Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary...

|By:, SA News Editor

Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary stock offering. The company plans to use the majority of the funds for research and development of its injectable acetaminophen drug Ofirmev.